within Pharmacolibrary.Drugs.N_NervousSystem.N06A_Antidepressants.N06AF03_Phenelzine;

model Phenelzine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.12,
    Cl = 9.800000000000001e-06,
    adminDuration = 600,
    adminMass = 30 / 1000000,
    adminCount = 1,
    Vd = 0.0019399999999999999,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0013833333333333334,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Phenelzine</td></tr><tr><td>ATC code:</td><td>N06AF03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>30</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.94</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.504</td><td>L/kg/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Phenelzine is a non-selective and irreversible monoamine oxidase inhibitor (MAOI) used as an antidepressant. It is approved primarily for the treatment of major depressive disorder, especially atypical, non-endogenous, or treatment-resistant depression. Its use today is limited due to dietary restrictions and potential adverse effects, but it remains an option when other antidepressants are ineffective.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N06AF03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Phenelzine;
